Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo Controlled, Single-blind, Randomized, Multi-center Phase 2B Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis

Next Previous
X
Search
Trial Profile

A Placebo Controlled, Single-blind, Randomized, Multi-center Phase 2B Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tonogenchoncel-L (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Kolon Life Science

    • Most Recent Events

    • 11 May 2015 According to a TissueGene media release, data from this study were presented at the 18th meeting of the American Society of Gene & Cell Therapy (ASGCT) 2015.
    • 11 May 2015 According to a TissueGene media release, data from this study were presented at the 12th World Congress of the International Cartilage Repair Society (ICRS) 2015.
    • 14 Nov 2012 TissueGene announces recruitment completion in a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top